Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance

Rhea-AI Summary

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) voiced support for the reintroduction of the bipartisan PASTEUR Act, which aims to incentivize development of new antimicrobials against antimicrobial resistance (AMR).

The company highlighted its proprietary Bisphosphocin® platform and lead candidate Nu-3, now preparing for Phase 2 as a topical therapy for infected diabetic foot ulcers.

Positive

• Proprietary Bisphosphocin® class targets infectious diseases with broad-spectrum, fast-acting antimicrobials
• In vitro activity reported against resistant strains including MRSA and VRE
• Nu-3 preparing to enter Phase 2 for infected diabetic foot ulcers, a major unmet need

Negative

• None.

Market reaction after Nu-3 Phase 2 development update: LABT -12.77% in the Jul 7 session

-12.77%

15 alerts

-12.77% Session close to close

+9.3% Peak Tracked

-12.2% Trough Tracked

$4.81M Market Cap

0.9x Rel. Volume

In the Jul 7 session, LABT declined 12.77%, reflecting a significant negative market reaction. Argus tracked a peak move of +9.3% during that session. Argus tracked a trough of -12.2% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -12.8% in the session following this news. A sharp decline would be consistent wit...

Analysis

The stock dropped -12.8% in the session following this news. A sharp decline would be consistent with past patterns, including moves of -7.8% and -36.65% after constructive Nu-3 updates. With substantial doubt about going concern previously disclosed, dilution or funding risk could remain a key overhang.

Key Figures

Planned trial phase: Phase 2

1 metrics

Planned trial phase Phase 2 Upcoming clinical development of Nu-3 for infected diabetic foot ulcer

Historical Context

5 past events · Latest: Jun 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 25	trial leadership update	Positive	-7.8%	Appointed David G. Armstrong as Study Chair and Scientific Advisor for Nu-3 Phase 2a.
Jun 22	patent grant	Positive	-7.2%	Secured new Australian composition-of-matter patent expanding Bisphosphocin IP portfolio.
Jun 16	investor presentation	Neutral	-0.7%	Scheduled Life Sciences Virtual Investor Forum presentation on strategy and Nu-3 program.
May 27	ip expansion	Positive	+3.0%	Expanded Nu-3 formulation patents to Australia and New Zealand, reinforcing global protection.
May 18	clinical progress	Positive	-36.6%	Reported positive data and manufacturing readiness supporting advancement of Nu-3 for iDFU.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive Nu-3 and IP updates have often been followed by negative price reactions, indicating a tendency for the stock to sell off on good news.

Key Terms

antimicrobial resistance, methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococci, infected diabetic foot ulcer

4 terms

antimicrobial resistance medical

"to address the growing global threat of antimicrobial resistance (AMR)"

Antimicrobial resistance is when microbes such as bacteria, viruses or fungi evolve so that medicines meant to kill them no longer work — like a lock changing so the old key no longer fits. For investors, this increases demand and cost for new treatments, prolongs hospital stays, prompts tougher regulation and can shrink sales of once-effective drugs, affecting pharmaceutical revenues, R&D spending and broader healthcare risk.

methicillin-resistant staphylococcus aureus medical

"against antibiotic resistant strains, including Methicillin-resistant Staphylococcus aureus (MRSA)"

A strain of the common bacteria Staphylococcus aureus that has evolved resistance to methicillin and many standard antibiotics, making infections harder to treat. Think of it like a lock that standard keys (typical antibiotics) no longer open; that raises the chance of longer hospital stays, extra treatments and higher costs. Investors care because resistant infections influence healthcare spending, drug and diagnostic demand, hospital liability and regulatory scrutiny, affecting healthcare, biotech and insurer financial outlooks.

vancomycin-resistant enterococci medical

"and Vancomycin-resistant Enterococci (VRE)"

Vancomycin-resistant enterococci are strains of common bacteria that have become immune to vancomycin, a last-resort antibiotic; they can cause hard-to-treat infections in hospitals and long-term care settings. Investors should care because outbreaks or rising resistance can increase healthcare costs, drive demand for new drugs and diagnostics, trigger regulatory action or litigation, and affect the revenue and reputation of firms tied to hospital care or antimicrobial products—think of them as pests that no longer respond to the usual pesticide.

infected diabetic foot ulcer medical

"Nu-3, as a topical therapy for infected diabetic foot ulcer (iDFU)"

A wound on the foot that occurs in people with diabetes and has become infected, often involving skin, underlying tissue, and sometimes bone; high blood sugar and poor circulation make these wounds slow to heal. Investors track this condition because it drives demand for treatments, wound-care devices and drugs, and because clinical trial results, regulatory approvals, or changes in treatment guidelines can affect the commercial prospects and reimbursement for companies developing therapies—think of it as a persistent, costly problem creating a steady market for medical solutions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company highlights its differentiated Bisphosphocin^® platform and lead clinical candidate Nu-3 as innovative approaches to addressing microbial infections and the risk of resistance development

SARASOTA, Fla., July 7, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin^® class, announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act, legislation designed to encourage the development of novel therapies to address the growing global threat of antimicrobial resistance (AMR).

"Antimicrobial resistance is rapidly becoming one of the greatest threats to global healthcare, making the development of novel anti-infective therapies more important than ever," said Kelvin Cooper, Ph.D., Chief Executive Officer of Lakewood-Amedex Biotherapeutics. "The reintroduction of the PASTEUR Act recognizes the urgent need for innovation in this critically important field. At Lakewood-Amedex Biotherapeutics, we believe our proprietary Bisphosphocin^® platform represents exactly the type of differentiated antimicrobial technology needed to help address resistant microbial infections, and we look forward to advancing the development of Nu-3 in patients with infected diabetic foot ulcers."

Lakewood-Amedex Biotherapeutics' proprietary Bisphosphocin^® class of compounds has been shown in vitro to rapidly kill bacteria through a pH and concentration dependent destabilization of the bacterial cell membrane. This mechanism of action not only leads to high in vitro activity against antibiotic resistant strains, including Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococci (VRE), but may also lower the probability of resistance development against the Bisphosphocin^® class as suggested by initial in-vitro resistance development data.

The Company's is preparing to enter Phase 2 clinical development with its lead product candidate, Nu-3, as a topical therapy for infected diabetic foot ulcer (iDFU). iDFUs represent a significant unmet medical need, affecting millions of patients worldwide and often leading to hospitalization and amputation if the infection cannot be controlled in an early stage. The emergence of antibiotic-resistant pathogens has further complicated treatment, underscoring the need for innovative therapeutic options such as Nu-3.

About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin^® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Lakewood-Amedex Biotherapeutics Inc.'s clinical development plans, regulatory strategy, anticipated trial timing, potential regulatory submissions or approvals, and the potential benefits, safety, efficacy and commercial potential of its Bisphosphocin® platform and product candidates. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks that clinical trials may not be initiated, completed or successful on expected timelines or at all; preclinical or clinical results may not be predictive of future results; product candidates may not demonstrate safety or efficacy or receive regulatory approval; and risks related to manufacturing, supply, financing and other matters described in the company's SEC filings, including under "Risk Factors." Forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to update them except as required by law.

Contact

Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-supports-reintroduction-of-the-pasteur-act-and-focus-on-combating-antimicrobial-resistance-302817338.html

SOURCE Lakewood-Amedex Biotherapeutics Inc.

FAQ

What did Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) announce about the PASTEUR Act in July 2026?

Lakewood-Amedex Biotherapeutics announced support for reintroduction of the bipartisan PASTEUR Act to combat antimicrobial resistance. According to Lakewood-Amedex Biotherapeutics, this legislation is designed to encourage development of novel anti-infective therapies addressing the growing global threat of antimicrobial resistance.

What is Lakewood-Amedex Biotherapeutics’ Bisphosphocin platform and how does it work?

The Bisphosphocin platform is a novel class of potent, fast-acting, broad-spectrum antimicrobials. According to Lakewood-Amedex Biotherapeutics, Bisphosphocin compounds kill bacteria in vitro by pH- and concentration-dependent destabilization of the bacterial cell membrane, showing activity against antibiotic-resistant strains like MRSA and VRE.

What is Nu-3, Lakewood-Amedex’s lead clinical candidate, being developed for?

Nu-3 is being developed as a topical therapy for infected diabetic foot ulcers (iDFU). According to Lakewood-Amedex Biotherapeutics, the company is preparing to enter Phase 2 development, targeting a serious unmet need that can lead to hospitalization and amputation if poorly controlled.

How might Nu-3 address antimicrobial resistance in infected diabetic foot ulcers for LABT?

Nu-3 is intended to treat infected diabetic foot ulcers where antibiotic-resistant pathogens complicate care. According to Lakewood-Amedex Biotherapeutics, initial in vitro resistance development data suggest its Bisphosphocin class may lower the probability of resistance developing compared with traditional antibiotics, though this remains early-stage evidence.

What antimicrobial-resistant bacteria does Lakewood-Amedex Biotherapeutics report activity against with Bisphosphocins?

Bisphosphocin compounds have shown in vitro activity against antibiotic-resistant strains such as MRSA and VRE. According to Lakewood-Amedex Biotherapeutics, their membrane-destabilizing mechanism of action leads to rapid bacterial killing under specific pH and concentration conditions in laboratory testing.

Why are infected diabetic foot ulcers a strategic focus for Lakewood-Amedex and Nu-3?

Infected diabetic foot ulcers affect millions worldwide and can result in hospitalization or amputation. According to Lakewood-Amedex Biotherapeutics, rising antibiotic resistance further complicates treatment, underscoring the need for innovative topical options like Nu-3 targeting this high-burden, unmet medical need.